IBI-20089 is IBI’s first product to enter clinical trials. It is the first injectable intraocular sustained release product for the delivery of triamcinolone acetonide. IBI-20089 is designed to deliver triamcinolone acetonide for up to one year with a single intravitreal injection, with the duration of delivery volume dependent.

IBI-20089 is administered as a standard intravitreal injection that eliminates the need for additional devices or surgical procedures. Formulated as a gel, IBI-20089 forms a sphere in the posterior segment after intravitreal injection. This sphere gradually degrades and disappears as the drug is released in a controlled manner.


Clinical Trials

IBI has completed a Phase 1/2 clinical trial of IBI-20089 in patients with cystoid macular edema associated with retinal vein occlusion. The clinical trial included two dosing levels, a 25-µl dose designed to last six months and a 50-µl dose designed to last one year. The results of the clinical trial confirm the expected safety and efficacy characteristics of the product, along with the controlled-release attributes of the Verisome® technology.

A “Proof of Concept” trial using IBI-20089 in conjunction with Lucentis® targeting “wet” AMD is nearing completion.

There are more than 20 ocular diseases that IBI-20089 may eventually treat.



My Canadian Pharmacy is an informative service. All the information should not be used in the purposes to establish a diagnosis and prescribe a treatment plan. Our company is a vendor, not a drug manufacturer. We cooperate with drug manufacturers who distribute their products to us. We have no relation with Icon Bioscience and Verisome. They move to another domain. We bear no responsibility for any damage brought to your health. All the questions related to the drug quality should be addressed to the drug manufacturer directly.